| Mr Steven Daniel Factor, MD | |
|
1151 Old York Rd Ste 200, Abington, PA 19001-3816 | |
| (215) 957-9250 | |
| (215) 957-9254 |
| Full Name | Mr Steven Daniel Factor |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 8 Years |
| Location | 1151 Old York Rd Ste 200, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730472408 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abington Memorial Hospital | Abington, PA | Hospital |
| Doylestown Hospital | Doylestown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Abington Memorial Hospital | 3274437736 | 528 |
| Abington Neurological Associates Ltd | 3274518444 | 12 |
News Archive
It is well known that aspirin, a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reduces the risk of heart attack and stroke.
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.
The Blue Cross and Blue Shield of Minnesota Foundation today announced the launch of the Connect for Health Challenge, a new grantmaking initiative that will award up to $500,000 to eligible nonprofits, schools and local units of government to support efforts that strengthen social connections in low-income communities across Minnesota.
› Verified 8 days ago
| Entity Name | Amh Medical Staff Service Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356384457 PECOS PAC ID: 9830003813 Enrollment ID: O20031114000011 |
News Archive
It is well known that aspirin, a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reduces the risk of heart attack and stroke.
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.
The Blue Cross and Blue Shield of Minnesota Foundation today announced the launch of the Connect for Health Challenge, a new grantmaking initiative that will award up to $500,000 to eligible nonprofits, schools and local units of government to support efforts that strengthen social connections in low-income communities across Minnesota.
› Verified 8 days ago
| Entity Name | Abington Neurological Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154432227 PECOS PAC ID: 3274518444 Enrollment ID: O20040622000451 |
News Archive
It is well known that aspirin, a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reduces the risk of heart attack and stroke.
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.
The Blue Cross and Blue Shield of Minnesota Foundation today announced the launch of the Connect for Health Challenge, a new grantmaking initiative that will award up to $500,000 to eligible nonprofits, schools and local units of government to support efforts that strengthen social connections in low-income communities across Minnesota.
› Verified 8 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275858920 PECOS PAC ID: 3274437736 Enrollment ID: O20100628001035 |
News Archive
It is well known that aspirin, a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reduces the risk of heart attack and stroke.
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.
The Blue Cross and Blue Shield of Minnesota Foundation today announced the launch of the Connect for Health Challenge, a new grantmaking initiative that will award up to $500,000 to eligible nonprofits, schools and local units of government to support efforts that strengthen social connections in low-income communities across Minnesota.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Steven Daniel Factor, MD 1151 Old York Rd Ste 200, Abington, PA 19001-3816 Ph: (215) 957-9250 | Mr Steven Daniel Factor, MD 1151 Old York Rd Ste 200, Abington, PA 19001-3816 Ph: (215) 957-9250 |
News Archive
It is well known that aspirin, a non-selective, non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX), reduces the risk of heart attack and stroke.
Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.
The Blue Cross and Blue Shield of Minnesota Foundation today announced the launch of the Connect for Health Challenge, a new grantmaking initiative that will award up to $500,000 to eligible nonprofits, schools and local units of government to support efforts that strengthen social connections in low-income communities across Minnesota.
› Verified 8 days ago
Osman Kozak, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, 5 Toll, Abington, PA 19001 Phone: 215-481-3145 | |
Kandan Kulandaivel, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1151 Old York Rd Ste 200, Abington, PA 19001 Phone: 215-957-9250 Fax: 215-957-9254 | |
Sam Leon Carson, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 Old York Rd, Suite B, Abington, PA 19001 Phone: 215-972-1100 Fax: 215-886-3250 | |
Dr. Alex Glijansky, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1579 Old York Rd, Abington, PA 19001 Phone: 215-830-1262 Fax: 215-830-1263 | |
Joseph Danial, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1245 Highland Ave, Suite 308, Abington, PA 19001 Phone: 215-481-3133 Fax: 215-481-7570 | |
John Safa Khoury, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1151 Old York Rd Ste 200, Abington, PA 19001 Phone: 215-957-9250 Fax: 215-957-9254 | |
Dr. Rose Ries, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1200 Old York Rd Bldg Room308, Abington, PA 19001 Phone: 215-481-7594 |